African Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: A mediation analysis study

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2773-2779

  Meghani, Salimah H ^a   Kang, Youjeong ^a   Chittams, Jesse ^a   McMenamin, Erin ^b   Mao, Jun J ^b   Fudin, Jeffrey ^c,d  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF NURSING   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d WESTERN NEW ENGLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; OXYCODONE; ANALGESIC AGENT;

ADULT; AFRICAN AMERICAN; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PAIN SEVERITY; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; CHRONIC KIDNEY FAILURE; COMPLICATION; ETHNOLOGY; HEALTH CARE DISPARITY; METABOLISM; MIDDLE AGED; NEOPLASM; PAIN;

AFRICAN AMERICANS; ANALGESICS; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; OXYCODONE; PAIN; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84906821094     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7992     Document Type: Article

References (35)

1. Launay-Vacher V: Epidemiology of chronic kidney disease in cancer patients: Lessons from the IRMA study group. Semin Nephrol 30:548-556, 2010
2. Janus N, Launay-Vacher V, Byloos E, et al: Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103:1815-1821, 2010
3. Launay-Vacher V, Oudard S, Janus N, et al: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376-1384, 2007
4. Aapro M, Launay-Vacher V: Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 38:235-240, 2012
5. Droney J, Levy J, Quigley C: Prescribing opioids in renal failure. J Opioid Manag 3:309-316, 2007
6. Lipworth L, Mumma MT, Cavanaugh KL, et al: Incidence and predictors of end stage renal disease among low-income blacks and whites. PloS One 7:e48407, 2012
7. Anderson KO, Green CR, Payne R: Racial and ethnic disparities in pain: Causes and consequences of unequal care. J Pain 10:1187-1204, 2009
8. Cintron A, Morrison RS: Pain and ethnicity in the United States: A systematic review. J Palliat Med 9:1454-1473, 2006
9. Green CR, Anderson KO, Baker TA, et al: The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 4:277-294, 2003
10. Meghani SH, Byun E, Gallagher RM: Time to take stock: A meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. Pain Med Feb 13:150-174, 2012
11. Meghani SH, Polomano RC, Tait RC, et al: Advancing a national agenda to eliminate disparities in pain care: Directions for health policy, education, practice, and research. Pain Med 13:5-28, 2012
12. Street Rx. Street Prices for Prescription Drugs 2013. http://streetrx.com
13. National Kidney Foundation. Calculators for Health Care Professionals: GFR Calculators. http://www.kidney.org/professionals/kdoqi/gfr-calculator.cfm
14. Pöge U, Gerhardt T, Palmedo H, et al: MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 5:1306-1311, 2005
15. Kleber M, Cybulla M, Bauchmüller K, et al: Monitoring of renal function in cancer patients: An ongoing challenge for clinical practice. Ann Oncol 18:950-958, 2007
16. Ward SE, Carlson-Dakes K, Hughes SH, et al: The impact on quality of life of patient-related barriers to pain management. Res Nurs Health 21:405-413, 1998
17. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
18. Baron RM, Kenny DA: The moderatormediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173-1182, 1986
19. Preacher KJ, Hayes AF: SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods 717-731, 2004
20. Burgess DJ, van Ryn M, Crowley-Matoka M, et al: Understanding the provider contribution to race/ethnicity disparities in pain treatment: Insights from dual process models of stereotyping. Pain Med 7:119-134, 2006
21. Green AR, Carney DR, Pallin DJ, et al: Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med 22:1231-1238, 2007
22. Meghani SH: Corporatization of pain medicine: Implications for widening pain care disparities. Pain Med 12:634-644, 2011
23. Green CR, Ndao-Brumblay SK, West B, et al: Differences in prescription opioid analgesic availability: Comparing minority and white pharmacies across Michigan. J Pain 6:689-699, 2005
24. Morrison RS, Wallenstein S, Natale DK, et al: "We don't carry that:" Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med 342:1023-1026, 2000
25. Meghani S, Hanlon A, Robinson A, et al: Pain treatment outcomes among African-Americans and whites: Evidence of age-race disparities. Gerontologist 52:62, 2012
26. Meghani SH, Chittams J, Hanlon AL, et al: Measuring preferences for analgesic treatment for cancer pain: How do African-Americans and whites perform on choice-based conjoint (CBC) analysis experiments? BMC Med Inform Decis Mak 13:118, 2013
27. Meghani SH, Hanlon A, Bruner D, et al: Do subjective measures of adherence predict actual analgesic taking behavior for cancer pain? J Pain 12:S20, 2011
28. Meghani SH, Hanlon A, Robinson A, et al: Unique clusters and correlates of preference for analgesic treatment for cancer pain. Pain 7:119-134, 2013
29. Rhee YO, Kim E, Kim B: Assessment of pain and analgesic use in African American cancer patients: Factors related to adherence to analgesics. J Immigr Minor Health 14:1045-1051, 2012
30. Gaedigk A, Bradford LD, Marcucci KA, et al: Unique CYP2D6 activity distribution and genotypephenotype discordance in black Americans. Clin Pharmacol Ther 72:76-89, 2002
31. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27: 55-67, 2012
32. Gretton SK, Ross JR, Rutter D, et al: Plasma morphine and metabolite concentrations are associated with clinical effects of morphine in cancer patients. J Pain Symptom Manage 45:670-680, 2013
33. U.S. Food and Drug Administration. FDA News Release. FDA approves abuse-deterrent labeling for reformulated OxyContin. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm
34. Throckmorton DC: Abuse-deterrent properties of Purdue's reformulated OxyContin (oxycodone hydrochloride) extended-release tablets. Center for Drug Evaluation and Reserch, DHHS [Memo]. http://www.accessdata.fda.gov/drugsatfda- docs/nda/2013/022272Orig1s014-ODMemo.pdf
35. Coplan P: FDA's Abuse Deterrence Guidance: Food and Drug Law Institute Conference on Controlled Substances Regulation. Food and Drug Law Institute. http://www.fdli.org/docs/defaultdocument-library/coplan-oxycontin-reformulation- v2.pdf?sfvrsn-0